Treatment of stable angina pectoris with trimetazidine modified release in Indian primary-care practice

American Journal of Cardiovascular Drugs

Volumn 5, Issue 5, 2005, Pages 325-329

  Gupta, Rajeev ^a   Sawhney, Jitendra P S ^b   Narain, Varun S ^c  

^a Monilek Hospital and Research Centre   (India)

^b SIR GANGA RAM HOSPITAL   (India)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; FLAVEDON; GLYCERYL TRINITRATE; NICORANDIL; NITRIC ACID DERIVATIVE; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HEART PALPITATION; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; VERTIGO;

AGED; ANGINA PECTORIS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 24944567171     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200505050-00005     Document Type: Article

References (10)

1. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991; 338 (8774): 1036-9
2. Pepine CJ, Abrams J, Marks RG, et al. Characteristics of a contemporary population with angina pectoris: the TIDES investigators. Am J Cardiol 1994; 74 (3): 226-31
3. Lopaschuk GD. Fatty acid and glucose metabolism: a target for intervention. In: Hearse DJ, Apstein CS, Cobbe SM, et al., editors. Metabolic approaches to ischemic heart disease and its management. London: Science Press, 1998: 44-57
4. Szwed H, Pachocki R, Domzal-Bochenska M, et al. Efficacy and tolerance of trimetazidine in combination with conventional antianginal drugs in patients with stable effort angina. Diagn Treat Cardiol 1997; 4: 237-47
5. Paes AH, Bakker A, Sue-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997; 20 (10): 1512-7
6. Genissel P, Chodjania Y, Demolis JL, et al. Assessment of sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. Eur J Drug Metab Pharmacokinet 2004; 20 (1): 61-8
7. Sellier P, Broustet J. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35mg in patients with stable angina pectoris. Am J Cardiovasc Drugs 2003; 3 (5): 361-9
8. Michaelides AP, Spiropoulos K, Dimopoulos K, et al. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13 (1): 8-14
9. Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78 (4): 353-7
10. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMIPOL II). Eur Heart J 2001; 22: 2267-74